The estimated Net Worth of Donald H Picker is at least $459 Mille dollars as of 22 June 2024. Dr Picker owns over 1,766 units of Moleculin Biotech Inc stock worth over $20,460 and over the last 7 years he sold MBRX stock worth over $0. In addition, he makes $438,156 as Chief Scientific Officer at Moleculin Biotech Inc.
Dr has made over 3 trades of the Moleculin Biotech Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he exercised 1,766 units of MBRX stock worth $4,238 on 22 June 2024.
The largest trade he's ever made was exercising 16,167 units of Moleculin Biotech Inc stock on 16 June 2023 worth over $38,801. On average, Dr trades about 1,901 units every 37 days since 2017. As of 22 June 2024 he still owns at least 8,525 units of Moleculin Biotech Inc stock.
You can see the complete history of Dr Picker stock trades at the bottom of the page.
Dr. Donald H. Picker Ph.D. is the Chief Scientific Officer at Moleculin Biotech Inc.
As the Chief Scientific Officer of Moleculin Biotech Inc, the total compensation of Dr D at Moleculin Biotech Inc is $438,156. There are 3 executives at Moleculin Biotech Inc getting paid more, with Walter V. Klemp having the highest compensation of $778,144.
Dr D is 75, he's been the Chief Scientific Officer of Moleculin Biotech Inc since . There are no older and 10 younger executives at Moleculin Biotech Inc.
Donald's mailing address filed with the SEC is C/O MOLECULIN BIOTECH, INC., 5300 MEMORIAL DR., SUITE 950, HOUSTON, TX, 77007.
Over the last 8 years, insiders at Moleculin Biotech Inc have traded over $340,000 worth of Moleculin Biotech Inc stock and bought 433,338 units worth $371,310 . The most active insiders traders include Walter V Klemp, John M Climaco e Waldemar Priebe. On average, Moleculin Biotech Inc executives and independent directors trade stock every 75 days with the average trade being worth of $69,293. The most recent stock trade was executed by Walter V Klemp on 2 July 2024, trading 982 units of MBRX stock currently worth $2,357.
moleculin biotech, inc. is a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on discoveries made at m.d. anderson cancer center. our lead product candidate is annamycin, a phase ii clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as aml. we also have two pre-clinical small molecule portfolios, one of which is focused on the modulation of hard-to-target tumor cell signaling mechanisms and the recruitment of the patient’s own immune system. the other portfolio targets the metabolism of tumors.
Moleculin Biotech Inc executives and other stock owners filed with the SEC include: